Nickel (II) chloride schiff base complex: Synthesis, characterization, toxicity, antibacterial and leishmanicidal activity

• Published in: Chemico-biological interactions 2022-01, Vol.351, p.109714-109714, Article 109714
• Main Authors: Maia, Danielle O., Santos, Valdenice F., Barbosa, Cristina R.S., Fróes, Yuri N., Muniz, Debora F., Santos, Ana L.E., Santos, Maria H.C., Silva, Romério R.S., Silva, Cláudio G.L., Souza, Racquel O.S., Sousa, Joicy C.S., Coutinho, Henrique D.M., Teixeira, Claudener S.
• Format: Article
• Language: English
• Subjects: Amikacin - pharmacology; Animals; Anti-Bacterial Agents - chemistry; Anti-Bacterial Agents - pharmacology; Antibacterial; Artemia - drug effects; Coordination Complexes - chemistry; Coordination Complexes - pharmacology; Drug Synergism; Escherichia coli - drug effects; Gentamicins - pharmacology; Leishmania infantum - drug effects; Leishmanicidal; Microbial Sensitivity Tests; Nickel - chemistry; Parasitic Sensitivity Tests; Pseudomonas aeruginosa - drug effects; Schiff base; Schiff Bases - chemistry; Schiff Bases - pharmacology; Staphylococcus aureus - drug effects; Toxicity; Trypanocidal Agents - chemistry; Trypanocidal Agents - pharmacology
• ISSN: 0009-2797; 1872-7786
• DOI: 10.1016/j.cbi.2021.109714

The use of schiff base complex against microbial agentes a has recently received more attention as a strategy to combat infections caused by multidrug-resistant bacteria and leishmania. This study aimed to evaluate the toxicity, antibacterial and leishmanicidal activities of the nickel (II) chloride schiff base complex ([Ni(L2)] against Leishmania amazonensis promastigote, multi-resistant bacterial strains and evaluate to modulate antibiotic activity against multi-resistant bacterial. The schiff base complex was characterized by the techniques of elemental analysis, Fourier transform infrared spectroscopy (FTIR), UV–vis absorption spectroscopy and thermal analysis (TGA/DTG/DSC). The [Ni(L2)] complex presented moderate toxicity in saline artemia (LC50 = 150.8 μg/mL). In leishmanicidal assay, the NiL2 complex showed values of IC50 of (6.079 μg/mL ± 0.05656 at the 24 h), (0.854 μg/mL ± 0.02474, 48 h) and (1.076 μg/mL ± 0.04039, 72 h). In antibacterial assay, the [Ni(L2)] complex presented significant inhibited the bacterial growth of P. aeruginosa (MIC = 256 μg/mL). However, [Ni(L2)] complex did not present clinically relevant minimum inhibitory concentration (MIC ≥1024 μg/mL) against S. aureus and E. coli. The combination of [Ni(L2)] complex and antibacterial drugs resulted in the increased antibiotic activity of gentamicin and amikacin against S. aureus and E.coli multi-resistant strains. Thus, our results showed that [Ni(L2)] complex is a promising molecule for the development of new therapies associated with aminoglycoside antibiotics and in disease control related to resistant bacteria and leishmaniasis. •[Ni(L2)] complex inhibits the growth of Pseudomonas aeruginosa.•[Ni(L2)] complex increases the activity of antibiotics against multiresistant bacteria.•[Ni(L2)] complex presented moderate toxicity in saline artemia.•[Ni(L2)] complex inhibits the growth of Leishmania infantum.